Technology
Health
Pharmaceutical

Biohaven Pharmaceutical

$61.76
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.12 (1.84%) Today
-$0.07 (-0.11%) After Hours

Why Robinhood?

You can buy or sell BHVN and other stocks, options, ETFs, and crypto commission-free!

About

Biohaven Pharmaceutical Holding Company Ltd., also called Biohaven Pharmaceutical, is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. Read More The company was founded in September 2013 and is headquartered in New Haven, CT.

Employees
63
Headquarters
New Haven, Connecticut
Founded
2013
Market Cap
2.74B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
445.63K
High Today
$62.20
Low Today
$60.64
Open Price
$61.83
Volume
65.81K
52 Week High
$65.64
52 Week Low
$29.17

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
Research And Development
2017 IPO
US

News

NasdaqMay 8

Health Care Sector Update for 05/08/2019: BHVN,GHDX,JAZZ,PTLA

Top Health Care Stocks JNJ +0.27% PFE +0.32% ABT -0.49% MRK +0.73% AMGN -0.66% Health care stocks rose Wednesday, including a 0.6% gain for the NYSE Health Care Index while shares of health care companies in the S&P 500 also were up nearly 0.6% as a group. The Nasdaq Biotechnology index was climbing just over 0.3%. Among health care stocks moving on news: (+) Biohaven Pharmaceutical Holding Company Ltd ( BHVN ) rose over 6% after reporting additional safety and efficacy data from ongoing testing of ...

58
Markets InsiderMay 7

Biohaven Pharmaceuticals Reports First Quarter 2019 Financial Results And Advancements In Neuroinnovation Platforms

NEW HAVEN, Conn., May 7, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology company focused on advancing innovative therapies for neurological and neuropsychiatric diseases, reported financial results and business updates for the quarter ended March 31, 2019. Vlad Coric, M.D., CEO of Biohaven commented, "In the first quarter of 2019, we took key strategic steps to accelerate the regulatory review and advance the commercialization of rimegepant Zydis® Orally Diss...

70
Yahoo FinanceMay 2

Hedge Funds Have Never Been This Bullish On Biohaven Pharmaceutical Holding Company Ltd. (BHVN)

Is Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of news stories covering failed hedge fund investments and it is a fact that hedge funds' picks don't beat the market 100% of the time, but their consen...

97

Earnings

-$2.32
-$1.80
-$1.27
-$0.75
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 9, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.